Klotho Neurosciences, Inc. is expanding its development focus beyond neurodegenerative disorders to include complementary longevity and anti-aging technologies. The company is evaluating acquisitions and assembling a multidisciplinary team to target key biomolecules—such as alpha- and beta-Klotho, FOXO3, and anti-myostatin—to develop interventions aimed at preserving cognitive function, muscular strength, bone health, and overall organ health to delay age-related diseases.

Key points

• Deployment of proprietary KLTO-101 and KLTO-202 gene therapy candidates targeting neurodegenerative pathways, now advancing into broader anti-aging applications.
• Assembly of a multidisciplinary scientific team to evaluate biomolecular targets—including alpha-Klotho, beta-Klotho isoforms, FOXO3 transcription factors, and anti-myostatin—for longevity interventions.
• Strategic acquisition approach to integrate complementary technologies aimed at preserving cognitive function, muscle mass, bone density, and organ health across multiple age-related diseases.

Why it matters: This expansion leverages Klotho’s multimodal aging pathways to pioneer next-generation longevity therapeutics with the potential to delay multiple age-related diseases.